Taysha Gene Therapies, Inc. — Form D
Taysha Gene Therapies, Inc. of DALLAS, TX, a company, filed a Form D exempt-offering notice with the SEC on 2020-05-04. The offering totals $30.0M, of which $18.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-05-04
- Form: D
- Accession: 0001806310-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $30.0M
- Amount sold: $18.0M
- Remaining: $12.0M
- Investors: 9
- Date of first sale: 2020-03-04
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-366194
Issuer
- Name: Taysha Gene Therapies, Inc.
- CIK: 0001806310
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
- Phone: (214) 612-0000
Officers, directors & promoters (24)
| Name | Role | Location |
|---|
| Sean Nolan | Director | WALTHAM, MA |
| R.A. Session II | Director | Dallas, TX |
| R.A. Session II | Executive Officer | Dallas, TX |
| Paul B Manning | Director | West Chester, PA |
| Phillip B Donenberg | Director | Watertown, MA |
| Phillip P Donenberg | Director | Dallas, TX |
| Sean P Nolan | Director | Dallas, TX |
| Sean P Nolan | Executive Officer | Dallas, TX |
| Laura P Sepp-Lorenzino | Director | Dallas, TX |
| Sean P Stalfort | Director | Dallas, TX |
| Kamran P Alam | Executive Officer | Dallas, TX |
| Kathleen P Reape | Director | Dallas, TX |
| Sukumar P Nagendran | Director | Dallas, TX |
| Sukumar P Nagendran | Executive Officer | Dallas, TX |
| Laura B Sepp-Lorenzino | Director | Dallas, TX |
| RA Session II | Director | Dallas, TX |
| RA Session II | Executive Officer | Dallas, TX |
| Kathleen B Reape | Director | Dallas, TX |
| Kamran B Alam | Executive Officer | Dallas, TX |
| Suyash B Prasad | Executive Officer | Dallas, TX |
| Sukumar B Nagendran | Director | Dallas, TX |
| Sean A Nolan | Director | Dallas, TX |
| R. A Session II | Director | Dallas, TX |
| R. A Session II | Executive Officer | Dallas, TX |
Other filings by this issuer (3)
More